CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases.The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
